Gemtuzumab ozogamicin reduces relapse risk in FLT3/ITD acute myeloid leukemia: a report from the Children’s Oncology Group

PURPOSE: Gemtuzumab ozogamicin (GO), a calicheamicin-conjugated monoclonal antibody against CD33, has been used in the treatment of acute myeloid leukemia (AML). We evaluated the impact of the addition of GO to standard chemotherapy and hematopoietic stem cell transplant (HCT) in patients with FLT3/...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Clin Cancer Res
Hoofdauteurs: Tarlock, Katherine, Alonzo, Todd A, Gerbing, Robert B, Raimondi, Susana C, Hirsch, Betsy, Sung, Lillian, Pollard, Jessica A, Aplenc, Richard, Loken, Michael, Gamis, Alan S, Meshinchi, Soheil
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: 2015
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4834220/
https://ncbi.nlm.nih.gov/pubmed/26644412
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-15-1349
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items